|
Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A methodology for screening of Abeta modulating drugs was developed utilizing an Abeta-producing neuroblastoma cell line stably transfected with mutant human amyloid precursor protein, immunoprecipitation of Abeta peptides, and mass spectroscopic quantitation of Abeta(1-37)/Abeta(1-38)/Abeta(1-40)/Abeta(1-42) using an Abeta internal standard.
|
19702658 |
2009 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A monoclonal antibody against PN-II (designated mAbP2-1) recognized PN-II in immunoblots of serum-free culture medium from human glioblastoma cells and neuroblastoma cells, as well as in homogenates of normal and Alzheimer's disease brains.
|
2507928 |
1989 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, S14 treatment reverted the Aβ-induced reduction in mitochondrial mass in APP/PS1 mice and in the human neuroblastoma SH-SY5Y cells co-exposed to Aβ.
|
29458418 |
2018 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although BIN1 is known to have a role in endocytosis, and the processing of the amyloid precursor protein (APP) to form amyloid-β (Aβ) peptides is dependent on endocytosis, knockdown of BIN1 by targeted siRNA or the overexpression of BIN1 in a human neuroblastoma cell line (SH-SY5Y) had no effect on APP processing.
|
24205320 |
2013 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By comparing two neuroblastoma cell lines differing substantially in NEP expression, we show by chromatin immunoprecipitation (ChIP) that AICD is bound directly to the NEP promoter in high NEP-expresser (NB7) cells but not in low-expresser (SH-SY5Y) cells.
|
19057576 |
2009 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
By utilizing neuroblastoma N2a cells transfected with Swedish mutated human amyloid precursor protein (APP) (N2a/APPswe) and wild-type APP (N2a/APPwt) as cellular models of AD, we examined the alterations of histone acetylation at the promoter regions of PS1 and BACE1 in these cells.
|
25051175 |
2014 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Changes in morphology of neuroblastoma cells treated with all-trans retinoic acid combined with transfer of the C-terminal region of the amyloid precursor protein.
|
9591705 |
1998 |
|
Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
COS-1 cells doubly transfected with cDNAs for N141I mutant PS2 and human beta-amyloid precursor protein (betaAPP) or a C-terminal fragment thereof, as well as mouse Neuro2a neuroblastoma cells stably transfected with N141I mutant PS2 alone, secreted 1.5- to 10-fold more A beta ending at residues 42 (or 43) [A beta42(43)] compared with those expressing the wild-type PS2.
|
9050898 |
1997 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Effects of interleukin-1 and interleukin-6 on metallothionein and amyloid precursor protein expression in human neuroblastoma cells. Evidence that interleukin-6 possibly acts via a receptor different from the 80-kDa interleukin-6 receptor.
|
8392518 |
1993 |
|
Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Experimentally, increased PP2Ac-Yp307 was observed in mouse N2a neuroblastoma cells that stably express the human amyloid precursor protein with Swedish mutation (APPswe) compared with wild-type, and in the brains of transgenic APPswe/ presenilin (PS1, A246E) mice, which corresponded to the increased tau phosphorylation.
|
18208556 |
2008 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Exposure of human neuroblastoma cells to DDT or DDE increased levels of amyloid precursor protein.
|
24473795 |
2014 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of a carboxy-terminal region of the beta-amyloid precursor protein in a heterogeneous culture of neuroblastoma cells: evidence for altered processing and selective neurotoxicity.
|
1334198 |
1992 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression Profiles of SIRT1 and APP Genes in Human Neuroblastoma SK-N-SH Cells Treated with Two Epigenetic Agents.
|
27522594 |
2016 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, both HMI-1a3 and HMI-1b11 increased the levels of sAPPα relative to total sAPP and the ratio of Aβ42/Aβ40 in human SH-SY5Y neuroblastoma cells.
|
30138694 |
2018 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, in neuroblastoma neuro-2A cells and primary superior cervical ganglion neurons, where APP is highly expressed, the lack of APP leads to a dramatic increase in plasma membrane recruitment of endogenous arrestin 3 following α<sub>2A</sub>AR activation.
|
28646018 |
2017 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we determined that higher neuroblastoma expression of APP also associated with neurodegeneration, correlated with better neuroblastoma survival rates.
|
30394813 |
2018 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gamma-hydroxybutyrate, acting through an anti-apoptotic mechanism, protects native and amyloid-precursor-protein-transfected neuroblastoma cells against oxidative stress-induced death.
|
24456637 |
2014 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Glial conditioned medium alters the expression of amyloid precursor protein in SH-SY5Y neuroblastoma cells.
|
8297361 |
1994 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we show that treatment with HLJDT-M and its components RC, CP, and the main compound berberine on N2a mouse neuroblastoma cells stably expressing human APP with the Swedish mutation (N2a-SwedAPP) significantly decreased the levels of full-length APP, phosphorylated APP at threonine 668, C-terminal fragments of APP, soluble APP (sAPP)-α and sAPPβ-Swedish and reduced the generation of Aβ peptide in the cell lysates of N2a-SwedAPP.
|
24671102 |
2014 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we assessed the dual effects of lodostigil in terms of the molecular mechanism of neuroprotection and amyloid precursor protein (APP) regulation/processing by using an apoptotic model of neuroblastoma SK-N-SH cells.
|
16935943 |
2006 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we found that S-nitrosylation of O-linked N-acetylglucosaminyltransferase (SNO-OGT) was induced by β-amyloid peptide (Aβ) exposure to SK-N-MC and SK-N-SH human neuroblastoma cells.
|
26854602 |
2016 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the effect of the nongenomic pathway induced by glucocorticoid on amyloid precursor protein processing enzymes as well as Aβ production using male ICR mice and human neuroblastoma SK-N-MC cells.
|
28855330 |
2017 |
|
Neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the neuroprotective and restorative involvement of the DA DA-JC1 and liraglutide (Lg), a single GLP-1 receptor analogue, in vitro using human neuroblastoma (SH-SY5Y) against oxidative stress induced by oxygen peroxide (H<sub>2</sub>O<sub>2</sub>), and in vivo, in a mouse model of Alzheimer's disease (AD), APP/PS1.
|
31628935 |
2020 |
|
Neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we provide evidence that estrogen promotes Abeta degradation mainly through a principal Abeta degrading enzyme, neprilysin, in neuroblastoma SH-SY5Y cells.
|
19897485 |
2010 |
|
Neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we show that expression of a phosphomimetic variant of Ser-675 in APP (APP-S675E), in human neuroblastoma SK-N-AS cells, reduces secretion of the soluble APP ectodomain (sAPPα), even though the total plasma membrane level of APP was unchanged compared with APP levels in cells expressing APPwt or APP-S675A.
|
31604820 |
2019 |